Evidence map›Paper›PMID 36430307›Full record

ReviewInternational journal of molecular sciences2022

Anticarcinogenic Effects of Isothiocyanates on Hepatocellular Carcinoma.

Yuting Zhang, Huiting Huang, Libo Jin, Sue Lin

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Frontiers in pharmacology · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuting ZhangInstitute of Life Sciences, College of Life and Environmental Science, Wenzhou University, Wenzhou 325035, China.
Huiting HuangInstitute of Life Sciences, College of Life and Environmental Science, Wenzhou University, Wenzhou 325035, China.
Libo JinInstitute of Life Sciences, College of Life and Environmental Science, Wenzhou University, Wenzhou 325035, China.
Sue LinInstitute of Life Sciences, College of Life and Environmental Science, Wenzhou University, Wenzhou 325035, China.ORCID 0000-0003-2539-3157
Wenzhou University · CN

Funding

Basic Scientific Research Projects of Wenzhou N20210003
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for about 90% of cases. Sorafenib, lenvatinib, and the combination of atezolizumab and bevacizumab are considered first-line treatments for advanced HCC. However, clinical application of these drugs has also caused some adverse reactions such as hypertension, elevated aspartate aminotransferases, and proteinuria. At present, natural products and their derivatives have drawn more and more attention due to less side effects as cancer treatments. Isothiocyanates (ITCs) are one type of hydrolysis products from glucosinolates (GLSs), secondary plant metabolites found exclusively in cruciferous vegetables. Accumulating evidence from encouraging in vitro and in vivo animal models has demonstrated that ITCs have multiple biological activities, especially their potentially health-promoting activities (antibacterial, antioxidant, and anticarcinogenic effects). In this review, we aim to comprehensively summarize the chemopreventive, anticancer, and chemosensitizative effects of ITCs on HCC, and explain the underlying molecular mechanisms.

Indexed as

Anticarcinogenic AgentsCarcinoma, HepatocellularLiver NeoplasmsAnimalsIsothiocyanatesAnticarcinogenic AgentsIsothiocyanatesisothiocyanic acidanticarcinogenic activitychemopreventionchemosensitizationcombination therapieshepatocellular carcinomaisothiocyanates

Identifiers

PMID36430307
PMCPMC9693344
OpenAlexW4308697572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.